The impact of comorbidity upon determinants of outcome in patients with lung cancer

Lung Cancer

Volumn 87, Issue 2, 2015, Pages 186-192

  Grose, Derek ^a   Morrison, David S ^b   Devereux, Graham ^c   Jones, Richard ^a   Sharma, Dave ^d   Selby, Colin ^e   Docherty, Kirsty ^d   McIntosh, David ^a   Nicolson, Marianne ^f   McMillan, Donald C ^b   Milroy, Robert ^g  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d INVERCLYDE ROYAL HOSPITAL   (United Kingdom)

^e QUEEN MARGARET HOSPITAL   (United Kingdom)

^f ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^g GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Comorbidity; Epidemiology; Lung cancer; NSCLC; Outcomes; Treatment

Indexed keywords

AFATINIB; ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; NAVELBINE; PEMETREXED;

ACINAR ADENOCARCINOMA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; COHORT ANALYSIS; COLOMBIA; CONTROLLED STUDY; COSTA RICA; FEMALE; HUMAN; LEPIDIC ADENOCARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEXICO; MUTATION; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; AGED; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMORBIDITY; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROGNOSIS; RISK FACTOR; SCOTLAND; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; RISK FACTORS; SCOTLAND; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS;

EID: 84922484384     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.11.012     Document Type: Article

References (57)

1. Gregor A., Thomson C.S., Brewster D.H., Stroner P.L., Davidson J., Fergusson R.J., et al. Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax 2001, 56:212-217.
2. Janssen-Heijnen M.L.G., Gatta G., Forman D., Capocaccia R., Coebergh J.W. Variation in survival of patients with lung cancer in Europe. Eur J Cancer 1998, 34:2191-2196.
3. Berrino F., De Angelis R., Milena Sant M., Rosso S., Bielska-Lasota M., Coebergh J.W., et al. and the EUROCARE working group,: sSurvival for eight major cancers and all cancers combined for European adults diagnosed in 1995--99: results of the EUROCARE-4 study. Lancet Oncol 2007, 8:773-783.
4. M.J. Horner, L.A.G. Ries, M. Krapcho, Neyman N, Aminou R, Howlader N et al., SEER Cancer Statistics Review, 1975--2006, Based on November 2008 SEER Data Submission, Posted to the SEER Web Site, 2009, National Cancer Institute; 2009. Available at: Bethesda, MD, Available at: http://seer.cancer.gov/csr/1975_2006/.
5. Fry W.A., Phillips J.L., Menck H.R. Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer 1999, 86:1867-1876.
6. Laroche C., Wells F., Coulden R., Stewart S., Goddard M., Lowry E., et al. Improving surgical resection rate in lung cancer. Thorax 1998, 53:445-449.
7. Cartman M.L., Hatfield A.C., Muers M.F., Peake M.D., Haward R.A., Forman D. Lung cancer: district active retreatment rates affect survival. J Epidemiol Community Health 2002, 56:424-429.
8. Damhuis R.A., Schutte P.R. Resection rates and postoperative mortality in 7, 899 patients with lung cancer. Eur Respir J 1996, 9:7-10.
9. Birring S.S., Peake M.D. Symptoms and the early diagnosis of lung cancer. Thorax 2005, 60:268-269.
10. Grose D., Devereux G., Brown L., Jones R., Sharma D., Selby C., et al. Variation in comorbidity and clinical management in patients newly diagnosed with lung cancer in four Scottish centres. JTO 2011, 6(3):500-509.
11. Grose D., Morrison D.S., Devereux G., Jones R., Sharma D., Selby C., et al. Comorbidities in lung cancer: prevalence, severity and links with socioeconomic status and treatment. Postgrad Med J 2014, 90:305-310.
12. Potosky A.L., Saxman S., Wallace R.B., Lynch C.F. Population variations in the initial treatment of non-small cell lung cancer. JCO 2004, 22:3261-3268.
13. Earle C.C., Venditti L.N., Neumann P.J., Gelber R.D., Milton C.W., Potoskky A.L., et al. Who gets chemotherapy for metastatic lung Ccancer?. Chest 2000, 117:1239-1246.
14. Extermann M. Measuring co-morbidity in older cancer patients. Eur J Cancer 2000, 36:453-471.
15. Charlson M.E., Pompei P. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
16. Tammemagi M.C., Neslund-Dudas C.M.A., Simoff M., Kvale P. Smoking and lung cancer survival: the role of co-morbidity and treatment. Chest 2004, 125:27-37.
17. Janssen-Heijnen M.L.G., Smulders S., Lemmens V.E.P.P., Smeenk F.W.J.M., van Geffen H.J.A.A., Coebergh J.W.W. Effect of co-morbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004, 59:602-607.
18. Colinet B., Jacot W., Bertrand D., Lacombe S., Bozonnat M.C., Daures J.P., et al. A new simplified co-morbidity score as a prognostic factor in non-small-cell lung cancer: description and comparison with the Charlson's index. Br J Cancer 2005, 93:1098-1105.
19. Birim O., Pieter Kappetein A., Bogers A.J.C.C. Charlson co-morbidity index as a predictor of long-term outcome after surgery for non-small- cell lung cancer. Eur J Cardiothorac Surg 2005, 28:759-762.
20. Imperatori A., Harrison R.N., Leitch D.N., Rovera F., Lepore G., Dionigi G., et al. Lung cancer in Teesside (UK) and Varese (Italy): a comparison of management and survival. Thorax 2006, 61:232-239.
21. Asmis T.R., Ding K., Seymour L., Shepherd F.A., Leighl N.B., Winton T.L., et al. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada clinical trials group trials. J Clin Oncol 2008, 26:54-59.
22. Erridge S.C., Murray B., Williams L., Brewster D., Black R., Price A., et al. Improved survival from lung cancer in British Columbia compared to Scotland-are different treatment rates the whole story?. Lung Cancer 2009, 64:358-366.
23. Grose D., Devereux G., Milroy R. Co-morbidity in Lung Cancer. Important but Nlung cancer. Important but neglected. A review of the current literature. Clinical Lung Cancer 2011, 12:207-211.
24. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136(1):260-271.
25. Martin L., Watanabe S., Fainsinger R., Lau F., Ghosh S., Quan H., et al. Prognostic factors in patients with advanced cancer: use of the patient-generated subjective global assessment in survival prediction. J Clin Oncol 2010, 28:4376-4383.
26. Mor V., Laliberte L., Morris J.N., Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting Cancer 1984, 53:2002-2007.
27. Yates J.W., Chalmer B., McKegney F.P. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980, 45:2220-2224.
28. McMillan D.C. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009, 12:223-226.
29. Proctor M.J., Morrison D.S., Talwar D., Balmer S.M., O'Reilly D.S.J., Foulis A.K., et al. An inflammation-based prognostic score (mgps) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011, 104:726-734.
30. Wilop S., Crysandt M., Bendel M., Mahnken A.H., Osieka R., Jost E. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer, Onkologie 31:665-670. Onkologie 2008, 31:665-670.
31. Koch A., Fohlin H., Sorenson S. Prognostic significance of c-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. JTO 2009, 4:326.
32. Gagnon B., Abrahamowicz M., Xiao Y., Beauchamp M.-E., MacDonald N., Kasymjanova G., et al. Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non- small cell lung cancer. Br J Cancer 2010, 102:1113-1122.
33. Arrieta O., Ortega M., Rodrigueza G.V., Serna-Thome M.G., Flores-Estrada D., Diaz-Romero C., et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 2010, 10:50.
34. Forrest L.M., McMillan D.C., McArdle C.S., Angerson W.J., Dunlop D.J. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004, 90:1704-1706.
35. Forrest L.M., McMillan D.C., McArdle C.S., Angerson W.J., Dagg K., Scott H.R. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005, 92:1834-1836.
36. Brown D.J.F., Milroy R., Preston T., McMillan D.C. The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol 2007, 60:705-708.
37. Leung E.Y.L., Scott H.R., McMillan D.C. Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cutility of the pretreatment Glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. JTO 2012, 7(4):655-662.
38. McMillan D.C. The systemic inflammation-based Glasgow Prognostic Score: Aa decade of experience in patients with cancer. Cancer Treatment Reviews. Canc Treat Rev 2013, 39(5):534-540.
39. Laird B., Kaasa S., McMillan D.C., Fallon M.T., Hjermstad M.J., Fayers P., et al. Prognostic Factors in Patients with Advanced Cancer: A Comparison of Clinicopathological Factors and the Development of an Inflammation-Based prognostic system. Clin Cancer Res 2013, 19:5456-5464.
40. Bozzetti F., Santarpia L., Pironi L., Thul P., Klek S., Gavazzi C. The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow up of 414 patients. Ann Oncol 2014, 25(2):487-493.
41. West of Scotland Cancer Network 2011 Audit report. Audit report; 2011. www.woscan.scot.nhs.uk.
42. Scottish Intercollegiate Guidelines Network (SIGN). Management of Patients with Lung Cancer, 2005. Available at: patients with lung cancer; 2005. Available at: http://www.sign.ac.uk/pdf/sign80.pdf.
43. Office of the Chie f Statistician, Scottish Executive. Scottish Index of Multiple Deprivation 2006: Technical Report. Available at: http://www. index of multiple deprivation 2006: technical report. Available at: http://www.scotland.gov.uk/Publications/2006/10/13142913/0.
44. Na tional Collaborating Centre for Clinical Conditions,. Management of exacerbations of COPD,. Thorax 2004; 59:i131-.
45. Available at: http://www.ccs.ca/download/position_statements/Grading% 20of%20Angina.pdf20of%20Angina.pdf.
46. The Criteria Committee of the New York Heart Association Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels 9th Ecriteria for diagnosis of diseases of the heart and great vessels, 9th ed., 1994, Boston, MA; Little, Brown & Co. 1994, 253-256.
47. Lyden D., Lu M., Levine S., Brott T.J., Broderick J. Modified National Institutes of Health Stroke Scale for use in stroke clinical trials. Stroke 2001, 32:1310.
48. Morris J. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
49. Lung cancer in England Information from the National Lung Cancer Audit (NLCA). 2013 2013, 50.
50. National Institute for Health and Care Excellence,. The diagnosis and treatment of lung cancer, 2011, Available at: http://www.guidance.nice.org.uk/CG121.
51. Grose D., Devereux G., Brown L., Jones R., Sharma D., Selby C., et al. Simple and objective prediction of survival in patients with lung cancer; staging the host systemic inflammatory response. Lung Ca Int 2014, in press.
52. Deleuran T., Thomsen R.W., Norgaard M., Jacobsen J.B., Rasmussen T.R., Sogaard T. Comorbidity and survival of Danish lung cancer patients from 2000--2011: a population-based cohort study. Clinical Epidemiology Epidemiol 2013, 5(1):31-38.
53. Luchtenborg M., Jakobsen E., Krasnik M., Linklater K.M., Mellemgaard A., Møller H. The effect of comorbidity on stage-specific survival in resected NSCLC patients. EJC 2012, 48:3386-3395.
54. Ahn D.H., Mehta N., Yorio J.T., Xie Y., Yan J., Gerber D.E. Influence of Medical Comorbidities on the Presentation of Stage I-medical comorbidities on the presentation of stage I-III NSCLC. Clin Lung Cancer 2013, 14(6):644-650.
55. Wang S., Wong M.L., Hamilton N., Davoren J.B., Jahan T.M., Walter L.C. Impact of Age and Comorbidity on NSCLC Treatment in Older Vage and comorbidity on NSCLC treatment in older veterans. JCO 2012, 30(13):1447-1450.
56. Ganti A.K., Siedlik E., Marr A.S., Loberiza F.R., Kessinger A. Predictive ability of Charlson comorbidity index on outcomes from lung cancer. Am J Clin Oncol 2011, 34(6):593-596.
57. Girones R., Torregrosa D., Gomez-Codina J., Maestu I., Tenias J.M., Rosell R. Prognostic impact of comorbidity in elderly lung cancer patients: Uuse and comparison of two scores. Lung Cancer 2011, 72:108-113.